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Matrix metalloproteinases (MMPs) are a group of enzymes
responsible for the degradation of extracellular matrix that occurs
during tissue formation and remodelling (Matrisian, 1990). In
health, the activity of MMPs is regulated at several levels,
including their secretion as latent proenzymes and inhibition of
their active form by endogenous tissue inhibitor of metallo-
proteinases (TIMPs) (Kleiner and Stetler-Stevenson, 1993). It is
now recognized, however, that unregulated and excessive MMP
activity explains many of the behavioural features of cancer
(Liotta and Stetler-Stevenson, 1990), rheumatoid arthritis (Gordon
et al, 1993), osteoarthritis (O￿Byrne et al, 1995), inflammatory
bowel disease (Saarialho-Kere et al, 1996), neurodegenerative
diseases (Gijbels et al, 1992), and cerebral haemorrhage
(Rosenberg, 1995). Therefore, the inhibition of MMPs is a poten-
tial strategy for the development of novel treatments for these
diseases.
Screening of many synthetic MMP inhibitors in the early 1990s
identified marimastat as the first such compound to show good
absorption after oral administration to animals (Beckett et al,
1996). Subsequent administration to healthy volunteers suggested
a rapidly absorbed and well-tolerated drug, with an estimated
terminal elimination half-life of 8—10 h (Millar et al, 1998).
Marimastat is a potent and reversible inhibitor of MMPs,
exhibiting IC50s in the nanomolar range against interstitial collage-
nase (MMP-1), gelatinase A (MMP-2), gelatinase B (MMP-9),
matrilysin (MMP-7), stromelysin 1 (MMP-3) and metalloelastase
(MMP-12). It has little or no activity against unrelated metallopro-
teinases such as enkephalinase. Studies in animal cancer models
with marimastat and its predecessor, batimastat, indicated that
these compounds could successfully inhibit tumour growth and
metastasis (Brown and Giavazzi, 1995).
The potential action of marimastat in cancer is cytostatic by
inhibiting the breakdown of the extracellular matrix, thereby
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Summary Marimastat is a specific inhibitor of matrix metalloproteinases that has been shown to be effective in cancer models. A pilot,
escalating-dose study of oral marimastat was performed in patients with recurrent colorectal cancer, in whom evaluation of serological
response was made by measurement of carcinoembryonic antigen (CEA) levels. The study assessed the safety and tolerability of 4 weeks
administration of marimastat, and determined a dose range producing detectable serological effects. Patients were recruited with a serum CEA
level greater than 5 ng ml–1, and rising by more than 25% over a 4-week screening period. Patients were treated for 28 days and entered into
a continuation protocol if a serological response or clinical benefit was observed. Pharmacokinetic and safety data determined that groups of
patients were recruited sequentially at 25 mg and 50 mg twice daily, and, thereafter, 10 mg twice daily, 10 mg once daily, 5 mg once daily and
20 mg once daily. A biological effect (BE) was defined as a CEA value on day 28 no greater than on day 0; a partial biological effect (PBE) was
defined as a rise in CEA over the 28-day treatment period of less than 25%. Of 70 patients recruited, 63 completed the 28-day treatment period,
and 55 were eligible for cancer antigen analysis. Examination of the dose–effect relationships provides evidence for a causal relationship
between marimastat and biological effects: the proportion of patients with BE or PBE was higher with twice daily dosing (16 out of 25, 64%) than
with once daily dosing (11 out of 30, 37%) (P = 0.043, c2 test). Furthermore, the median rates of rise of CEA fell markedly during treatment
compared with the screening period for patients receiving twice daily marimastat (P < 0.0001), but not for patients receiving marimastat once
daily (P = 0.25). Musculoskeletal adverse events emerged as the principal drug-related toxicity of marimastat, occurring in a dose- and time-
dependent fashion. It was concluded that marimastat was associated with dose-dependent biological effects in cancer patients. The
occurrence of musculoskeletal side-effects define 25 mg twice daily as the upper limit of the dose range for continuous use in further studies.
Therefore, a dose range of 20 mg once daily to 25 mg twice daily seems appropriate for further studies, which should aim to demonstrate the
efficacy of the drug in terms of conventional clinical end points and describe the long-term tolerability of this novel agent.
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General Hospital, Southampton SO16 6YD, UKcausing the restriction of tumour growth. It is not cytotoxic and
would not be expected to cause reduction in tumour size in human
studies. As the drug￿s actions were anticipated to be subtle, it was
thought that trial design employing conventional radiological,
clinical or serological measurements of tumour response or
progression might fail to detect clinically important activity. An
alternative might be trials assessing ￿response￿ in terms of mainte-
nance of stable disease. However, it was not considered suitable
initially to treat patients for longer than 28 days with this new class
of drug. The relevance of disease stability over such a short period
is questionable. Therefore, a novel approach to the conduct of
phase I and II trials was undertaken in the early development of
marimastat.
It was proposed that changes in the levels of the glycoprotein
carcinoembryonic antigen (CEA) could be employed as a surro-
gate marker for the biological activity of marimastat in patients
with colorectal cancer. CEA has been used in the clinical manage-
ment of patients with colorectal cancer for more than three
decades (Gold and Freedman, 1965), and has found roles in the
detection of recurrent disease (Minton et al, 1985; Quentmeier et
al, 1990; Hida et al, 1996) and the monitoring of response to
chemotherapy in patients with advanced cancer (Allen-Mersh et
al, 1987; Ward et al, 1993). Correlations have been observed
between the rate of rise of CEA and reduced survival, and between
falls in CEA and improved survival, in patients being treated for
colorectal cancer (Sugarbaker et al, 1976; Allen-Mersh et al, 1987;
Nakayama et al, 1997). These correlations are not obscured by
substantial interpatient variability in baseline CEA concentrations
(Allen-Mersh et al, 1987).
Expression of many of the MMPs has been reported in
colorectal cancer (Levy et al, 1991; Gray et al, 1993; Zucker et al,
1993; Newell et al, 1994); increased expression of gelatinase B
(MMP-9) has been implicated as an independent predictor of
recurrence and outcome (Zeng et al, 1996), and expression of
matrilysin (MMP-7) has been correlated with disease progression
(Ishikawa, 1996). Moreover, MMP inhibitors have been shown to
be effective in reducing tumour growth and spread in several
xenograft models of human colorectal cancer (Wang et al, 1994;
Watson et al 1995; An et al, 1997).
On the basis of these observations, colorectal cancer was chosen
as one of the target cancers to be assessed in the marimastat early
trial programme, some of the results of which have now been
published (Nemunaitis et al, 1998). By examining the effect of
marimastat upon the rate of rise of serum CEA, this study aimed to
explore the relationship between marimastat dosing and detectable
biological effects. In addition, it aimed to evaluate the tolerability
of a range of doses and schedules of marimastat in patients with
advanced colorectal cancer. The study was sponsored by British
Biotech Pharmaceuticals, Oxford, UK, who supplied the drug.
PATIENTS AND METHODS
Patients
Patients with previously resected histologically proven colorectal
cancer were selected for this study on the basis of a level of CEA
above 5 ng ml—1, and rising by 25% or more over a 4-week period,
before study entry. An Eastern Cooperative Oncology Group
(ECOG) performance status of 0—2 and a predicted survival of
3 months or more was required. Patients may have received
prior chemotherapy, but were excluded if (i) surgery had been
performed in the previous month; (ii) bilirubin and liver enzymes
were greater than three times, and creatinine greater than twice,
the upper limit of normal; (iii) albumin was less than 25 gl—1; or
(iv) if there was evidence of weight loss greater than 10% in the
previous 3 months.
Patients were recruited into the study from seven centres, five in
the UK and two in Belgium. The protocol and protocol amend-
ments were reviewed by the research ethics committee at each
investigational centre and approved. All patients provided
witnessed written informed consent to participate in the study, and
the study was conducted in accordance with the European
Guidelines on Good Clinical Practice.
Objectives
This study aimed to investigate the effect of marimastat on the rate
of rise of CEA and to define the safety and tolerability of 4 weeks
administration of the drug. Together with the assessment of the
pharmacokinetic profiles of marimastat, these measures were to
determine an effective dose range, with adequate tolerability for
longer term studies.
Treatment
Gel capsules containing 5, 10, 25 or 50 mg of marimastat were
provided by British Biotech Pharmaceuticals, Oxford, UK.
Patients received their first dose of marimastat after satisfactory
completion of screening procedures at —5 and —1 weeks. It was
originally intended in this open pilot dose-escalation study that
sequential groups of ten patients would receive doses of 25, 50 and
100 mg twice daily for a period of 28 days. The starting dose of
25 mg twice daily was decided on the basis of data from healthy
volunteer studies (Millar et al, 1998), and escalation beyond each
dose level was dependent on satisfactory safety data received from
patients treated up to that time. Each group was to complete
recruitment before the study progressed to the next dose. In the
event, pharmacokinetic and safety data ruled out escalation
beyond the 50 mg dose, and dose de-escalation occurred, with
sequential groups of patients recruited at 10 mg twice daily, 10 mg
once daily, 5 mg once daily and 20 mg once daily.
Continued administration of marimastat was allowed beyond 28
days in patients who were considered to be responding to therapy
as defined by the response criteria below, or when in the opinion of
the investigator the patient was benefiting from the drug. Dose
reduction was possible when patients experienced marimastat-
related toxicity of less than grade 3.
End points
After screening, samples were taken for the measurement of CEA
at days 0, 7, 14 and 28. CEA measurements were made at local
laboratories with each patient￿s results being measured by the
same laboratory. Inter-laboratory variability was not anticipated to
confound results because rates of rise of CEA levels rather than
absolute values were used for analysis of results. Criteria for
response were defined as follows: a biological effect was defined
as a rate of rise of CEA during the 28-day marimastat treatment
period †0%; a partial biological effect was defined as a rate of rise
of CEA during marimastat treatment >0% and †25%; non-respon-
ders were defined as those patients displaying a rate of rise of CEA
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of disease progression, or who died within 6 weeks of starting
treatment. In the absence of evaluable screening or treatment data,
patients were considered to be non-evaluable.
Because samples were not always taken at scheduled times, a
computerized preanalysis algorithm was devised which selected
the most appropriate antigen measurements for analysis in an unbi-
ased manner (see below). In these analyses, 48 out of 55 (87%)
evaluable patients had the required screening antigen measure-
ments recorded within 6 weeks before entry, and 45 out of 55
(82%) had treatment antigen values recorded at the precise proto-
colized times.
After review of the results of changes in CEA levels, analysis
was also made of the effect of marimastat on lactate dehydro-
genase (LDH). This enzyme is a marker of cellular turnover and
destruction and is biochemically unrelated to cancer antigen
expression. LDH levels have been used to guide prognosis in
patients with cancer, and have been shown to be associated with
time to disease progression and predictive of survival in colorectal
cancer (Schwartz, 1992; Fountzilas et al, 1996).
Blood samples were taken for pharmacokinetic evaluation on
days 0 (0 and 2h), 14 and 28. Further samples were taken in
patients receiving marimastat for more than 28 days. Clinical
chemistry and haematology, urinalysis and vital signs were moni-
tored throughout the study. All adverse events were recorded,
whether thought related to marimastat or not.
Application of algorithm for tumour marker
measurement
The computerized algorithm was derived from the study protocol
and stipulated that patients were to have two screening (S1 and S2)
and two treatment (T1 and T2) CEA values determined at the same
laborator y. S1 was to be measured more than 2 weeks before S2,
but less than 13 weeks before the start of the study. S2 must have
been taken within 4 weeks of the start of treatment, and be greater
than 5ng ml—1. The rate of rise of CEA averaged over 28 days must
have been ‡25%. T1 was required to be measured less than 7 days
before, and less than 2 days after the start of treatment. T2 was to
be measured between 22 and 34 days after the start of treatment,
but no more than 2 days after the discontinuation of treatment. All
patients who failed to meet one or more of these inclusion criteria
were to be excluded from the primary analyses.
Statistical analysis
Categorical data were analysed using th e c2 test. Differences
between patient groups at baseline were analysed using
Kruskal—Wallis and Wilcoxon tests. Continuous data were
analysed by the Wilcoxon signed rank test and Wilcoxon rank sum
test. Before results were analysed, a comparison of patients
receiving once daily doses and patients receiving twice daily doses
was planned.
RESULTS
Patient population
A total of 70 patients were recruited, of whom seven did not
complete the 28-day treatment period; five of these seven were
evaluable for toxicity and two failed to attend. Three of the five
discontinued because of adverse events, one patient died and one
experienced disease progression. Of 63 patients completing the
first part of the study, 31 continued receiving marimastat for
periods of up to 316 days.
Patient characteristics are listed in  Table 1 including data by
dose group. Colorectal adenocarcinoma was confirmed in 65
patients; the remaining five patients were recorded as having
colorectal cancer of unconfirmed histological type. All but two
patients had undergone surgery for their cancer, and most had
received chemotherapy, predominantly for treatment of recurrent
disease. At the time of entry into the study, 68 patients had radio-
logical evidence of visceral metastatic disease, one had lymphatic
metastases, and one had regional disease onl y. Patients were
recruited in approximately equal numbers to each of the dose
groups. No baseline characteristics were significantly di fferent
between dose groups, or between patients treated by once daily or
twice daily doses.
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Table 1Patient characteristics
Characteristics Total 5mg 10mg 20mg 10mg 25mg 50mg
once daily once daily once daily twice daily twice daily twice daily
No. of patients 70 11 12 14 11 11 11
No. with evaluable CEA data 55 9 9 12 8 9 8
No. continuing after day 28 31 6 1 9 6 3 6
Age
Mean 63 64 63 62 62 60 65
Range 40–87 45–81 47–75 46–87 50–81 40–74 59–71
Stage at first presentation
II 11 1 2 3 2 2 1
III 42 10 6 7 7 5 7
IV 17 0 4 3 2 4 3
Screening rate of rise of CEA % 56 60 59 61 57 91 35
Albumin gl–1 38 35 36 36 42 36 40
LDH Ul–1 596 633 564 616 320 959 658Efficacy assessments
In total, 55 (79%) of the 70 patients were eligible for cancer
antigen analysis under the rules of the algorithm. The 15 patients
excluded from analysis comprised three who failed to complete
the study (for reasons other than death or disease progression, this
group being categorized as non-responders), 11 who had absent or
invalid screening or treatment data, and one whose screening rate
of rise was less than 25%.
The results categorized by biological effect (†0% rise) and
partial biological effect (†25%, >0% rise) are shown by dose group
in Table 2 and Figure 1. Only partial biological effects were
observed at 5 and 10 mg once daily. Both biological and partial
biological effects were observed in the other four dose groups, with
the highest combined effects seen at 10 and 50 mg twice daily. The
proportion of patients showing a biological or partial biological
effect was higher with twice daily than once daily dosing (16 out of
25, 64% compared with 11 out of 30, 37%, P = 0.043, c2 test). An
additional eight patients with screening data ineligible by algorithm
but with eligible treatment data were included in an intention to
treat analysis. Results were essentially unchanged; the proportion
of patients showing a biological or partial biological effect was
higher with the twice daily than once daily dosing (20 out of 30,
67% compared with 14 out of 33, 42%, P = 0.054, c2 test).
Median rates of rise of CEA at screening and during treatment
are illustrated in Figure 2. Small falls were apparent in those
patients receiving 5 and 10 mg once daily. Changes were more
substantial in the higher dose groups, and the difference in those
patients receiving twice daily doses of marimastat was more
evident (P < 0.0001) than in those patients receiving marimastat
once daily (P = 0.25). The same relationship was observed when
the median differences between screen and treatment rates of rise
of CEA were charted (Figure 3). The median screening rate of rise
of CEA was higher in those patients receiving 25 mg twice daily
(91%) than for other groups (35—61%) (Figure 2), and this may
explain the relatively low proportion of patients in this group
showing biological or partial biological effects (Figure 1).
Trough plasma levels of marimastat are presented by dose in
Table 3. For a given dose, trough plasma levels were three- to four-
fold higher than that observed in healthy volunteers (Millar et al,
1998). This increase is probably related to pharmacokinetic differ-
ences between young healthy males and older patients with
advanced malignancy. Considerable intersubject variability was
apparent within dose groups, although, with the exception of the
group receiving 10 mg once daily, an approximately linear rela-
tionship with mean values was observed with increasing dose.
Patients were divided into quartiles on the basis of trough plasma
levels, and the median difference in treatment and screening
percentage rate of rise of CEA for each group was calculated.
Median differences for the low (†23.0 mg l—1), low/middle (>23.0
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Table 2 Biological responses observed for patients with evaluable
screening and treatment CEA results
Dose BE (%) PBE (%) NR (%) Total NE
5 mg once daily 0 (0) 3 (33) 6 (67) 9 2
10 mg once daily 0 (0) 3 (33) 6 (67) 9 3
20 mg once daily 4 (33) 1 (8) 7 (58) 12 2
All once daily doses 4 (13) 7 (23) 19 (63) 30 7
10 mg twice daily 2 (25) 4 (50) 2 (25) 8 3
25 mg twice daily 1 (11) 2 (22) 6 (67) 9 2
50 mg twice daily 6 (75) 1 (13) 1 (13) 8 3
All twice daily doses 9 (36) 7 (28) 9 (36) 25 8
BE, biological effect; PBE, partial biological effect; NR, non-responder, NE,
non-evaluable.
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Figure 1 Percentage biological effect (BE) and partial biological effects
(PBE) by dose group, in which BE is defined as a CEA value on day 28 no
greater than that on day 0 and PBE is defined as a rise in CEA over the 28-
day treatment period of less than 25%
Figure 2 Median percentage rate of rise of CEA during screening and
treatment with marimastat, by dose group with upper and lower quartiles
Figure 3 Median difference between screening and treatment percentage
rate of rise of CEA, by dose group with upper and lower quartiles
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A retrospective analysis was performed on the effect of marima-
stat on LDH. At day 28, the median percentage changes from base-
line for the 5 mg once daily, 10 mg once daily, 20 mg once daily,
10 mg twice daily, 25 mg twice daily and 50 mg twice daily
groups were +12.4%, +9.0%, —4.4%, —0.7%, —7.8% and —12.4%
respectively. The changes in LDH levels were not significantly
different when comparing twice and once daily dosing (P = 0.06).
Safety assessments
Sixty-eight patients were assessable for toxicity. Adverse events
occurring in at least three patients in one of the dose groups during
the study period are presented in Table 4. This table incorporates
all reported events, whether thought to be related to marimastat or
not. The most commonly reported events were those related to the
musculoskeletal and gastrointestinal systems. Four serious events
were reported as being possibly related to marimastat, including
single cases of fatigue, general body pain, renal dysfunction and
jaundice. There were no obvious adverse trends in laboratory
values with marimastat treatment, although many out of range
values were recorded both before and during treatment.
When considering adverse events reported to be definitely,
probably or possibly related to marimastat, it was apparent that the
principal toxicity of marimastat reported in this study was the
occurrence of reversible musculoskeletal events. Symptoms
included myalgia, arthralgia and tendinitis, predominantly of the
upper limbs. The times of occurrence of musculoskeletal symp-
toms requiring dose reduction or withdrawal are described in Table
5. Although musculoskeletal events occurred in a dose- and time-
dependent fashion, no clear relationship was observed between the
occurrence of musculoskeletal adverse events and trough serum
levels of marimastat. Four other patients who completed the 28-
day study period suffered musculoskeletal symptoms of at least
moderate severity and, possibly for this reason, were not entered
into the continuation protocol.
DISCUSSION
This study has taken a novel approach to the clinical development
of a cytostatic agent in attempting to show biological activity by
the effect of marimastat on the rates of rise of cancer antigens. It
has succeeded in this by showing changes in the rates of rise of
CEA in colorectal cancer which were suggestive of a dose-
dependent biological effect. These results allow estimation of a
dose range suitable for longer term controlled studies, which might
hope to establish the clinical efficacy of marimastat.
Biological and partial biological effects were seen most
commonly in the patients treated with higher doses of marimastat;
a significant increase in response was observed between those
patients receiving marimastat twice daily and those receiving
marimastat once daily. The dose-dependent effect on rate of rise of
CEA was also apparent when assessing the relative falls in rate of
rise of CEA between the dose groups. Increased effects on the rate
of rise of CEA were observed with higher trough plasma levels of
marimastat, although this was not statistically significant.
Selection of a population of cancer patients with rapidly rising
CEA levels during screening would tend to produce regression to
the mean during the study period. This may contribute to the falls
in the rate of rise of CEA occurring in patients treated at the two
lowest doses (5 and 10 mg once daily). It seems reasonable to
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Table 3 Trough plasma levels (mg l–1) by dose
Dose n Range Mean (SE) Median
5 mg once daily 5 8.2–22.7 12.6 (2.6) 11.5
10 mg once daily 10 10.2–100.9 45.2 (10.1) 47.1
20 mg once daily 11 8.2–102.4 41.5 (9.9) 25.1
10 mg twice daily 11 21.5–131.5 52.0 (10.5) 40.6
25 mg twice daily 9 69.8–314.6 165.8 (28.3) 145.4
50 mg twice daily 9 138.0–753.4 286.2 (67.0) 182.4
n, number of patients with recorded trough plasma levels.
Table 4 Summary of adverse events occurring in 28-day study period (all
causalities)
Once-daily doses Twice-daily doses
5m g 1 0m g 2 0m g 1 0m g 2 5m g 5 0m g
Total recruited 11 12 14 11 11 11
No. with events 11 12 12 10 11 11
Arthralgia 4 2 4 4 0 4
Back pain 1 0 2 2 2 0
Myalgia 2 2 2 3 3 5
Abdominal pain 5 4 2 2 3 0
Anorexia 2 1 1 1 4 1
Constipation 4 2 1 1 0 1
Mouth dry 0 1 3 0 0 0
Nausea 2 0 2 0 4 0
Dyspnoea 1 1 0 4 0 2
Ascites 0 3 2 0 1 1
Fatigue 1 2 2 2 0 3
Table 5 Musculoskeletal events leading to dose reduction or treatment withdrawal
Dose n No. continuing No. reducing dose Time to event
after day 28 or withdrawing (days)
5 mg once daily 11 6 1 21
10 mg once daily 12 1 0 –
20 mg once daily 14 9 6 28, 49, 70, 76, 120, 175
10 mg twice daily 11 6 4 41, 66, 95, 115
25 mg twice daily 11 3 0 –
50 mg twice daily 11 6 7 5, 16, 39, 45, 56, 58, 101conclude, however, that the more pronounced reductions observed
in the four higher dose groups were the result of treatment. A treat-
ment effect on the rate of rise of CEA can be subject to a variety of
interpretations, including the possibility of biochemical modula-
tion of CEA synthesis or cancer antigen shedding unrelated to
tumour progression. This seems unlikely in view of the lack of
effect of marimastat on CEA shedding in in vitro studies with
colorectal cancer cells (data not shown) and the apparent dose-
related reduction in LDH, an important marker of tumour activity
(Schwartz, 1992; Fountzilas et al, 1996). Finally, as a non-random-
ized study, patients with different characteristics could have been
unevenly distributed across the marimastat doses, favouring the
higher dose groups. Demographic data do not support this sugges-
tion, although unmeasured variables may exist with the potential
to confound results.
Marimastat was well-tolerated in this study, with musculo-
skeletal events emerging as the principal treatment-related toxi-
city. Symptoms were more severe and developed more rapidly at
the highest dose (50 mg twice daily), although were reversible.
Other adverse events were encountered commonly, but in most
instances reflected the nature of the underlying disease process
rather than a drug effect. The four serious adverse events thought
possibly related to marimastat also were thought at least as likely
to be related to the underlying disease.
On the basis of the safety and tolerability data, and the effects
on cancer antigens, a dose range of 20 mg once daily to 25 mg
twice daily seems appropriate for longer term, randomized and
controlled studies. These studies should aim to define both the
efficacy of the drug in terms of hard clinical end points such as
patient survival or ￿response￿ in terms of disease-free survival, and
the long-term tolerability of this novel agent.
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